JHX: Building Materials Behemoth - AZEK's Acquisition Ambition Meets Valuation Reality
Strong Sell rating with fair value $11.26 vs current $30.98 - 83% overvaluation despite solid fundamentals and AZEK synergies
View noteStrong Sell rating with fair value $11.26 vs current $30.98 - 83% overvaluation despite solid fundamentals and AZEK synergies
View noteSpeculative transformation play trading at 76% discount to $0.74 fair value. Strong balance sheet ($40.6m net cash) provides runway but execution risk substantial with 30% management track record.
View noteRevolutionary HAMR technology targets 75% cost reduction in $7B titanium market. Fair value $0.95 vs current $0.35 implies 171% upside potential.
View noteHOLD rating with $3.28 fair value vs $3.73 current price. Revenue growth moderating to 5.7% CAGR with margin compression pressures.
View noteHOLD rating with $3.60 fair value vs $5.96 current price. Strong demographics offset by execution risks and regulatory headwinds.
View noteAustralia's #2 diagnostic imaging provider trading at 129% premium to $1.16 fair value. High leverage, workforce constraints, and technology disruption create asymmetric downside risk.
View noteTrading at $1.00 vs fair value $0.88. Business quality 5.9/10, EBITDA margins compressing 49.9% to 44.7%. Development pipeline finite, competitive moat narrowing 4-6 years.
View noteHOLD rating with $2.26 fair value vs $2.65 current price. Strong 5.85% dividend yield offset by customer concentration risks and margin compression pressures.
View noteHOLD rating with $4.75 fair value vs $5.27 current price. 98.5% occupancy but office headwinds and 7.2x leverage create challenging outlook.
View noteHOLD rating with $3.61 fair value vs $4.27 current price. Exceptional ROIC 71.6% offset by cyclical peak timing concerns and inevitable margin compression.
View noteTrading at $35.89 vs fair value $18.38 (95% premium). Development margins at 47.8% face compression to 42%. ROIC 8.2% trails WACC 9.6%. Quality business, extreme valuation.
View noteGenesis Minerals trades at A$4.53 versus fair value A$1.75 (-61%), with 49.4% EBITDA margins facing compression to 39% as grade depletes from 2.7g/t to 2.0g/t. ROIC 21.8%, narrow moat (6-8 years), high execution risk on A$1.5bn expansion.
View note